Vihko R, Alanko A, Isomaa V, Kauppila A
Med Oncol Tumor Pharmacother. 1986;3(3-4):197-210. doi: 10.1007/BF02934996.
The predictive value of female sex steroid, estrogen and progesterone, receptor (ER and PR, respectively) assays in breast, endometrial and ovarian cancer is reviewed with emphasis on comparative aspects of these malignant tumors in relation to their hormone dependency. The endocrine etiology of these three tumor types seems to be at least partly different, and so is the expression of these receptors in normal and malignant tissues of the breast, endometrium and ovary. There is a tendency for decreased receptor concentrations and disappearance of these receptors in association with advancement of these malignancies. There is also a decrease in the presence and concentrations of ER and PR in relation to loss of differentiation in breast and endometrial cancer. Receptor analyses have an established position in the selection of patients with advanced breast cancer for endocrine treatment, and they give promise of a similar application in endometrial cancer and in endometrioid cancer of the ovary. It is not clear whether the disease-free interval is related to the presence or concentrations of ER or PR as such in the tumor tissue. There is better survival in breast cancer patients with receptor-positive tumors, which might be due to a response to endocrine treatment. The same seems to be true for patients with endometrial cancer. Future progress in the application of female sex steroid receptor analyses in breast, endometrial and ovarian cancer needs additional controlled clinical trials and more highly developed receptor assays.
本文综述了女性性激素（雌激素和孕激素）受体（分别为ER和PR）检测在乳腺癌、子宫内膜癌和卵巢癌中的预测价值，重点在于这些恶性肿瘤在激素依赖性方面的比较。这三种肿瘤类型的内分泌病因似乎至少部分不同，乳腺、子宫内膜和卵巢的正常及恶性组织中这些受体的表达情况也是如此。随着这些恶性肿瘤的进展，受体浓度有降低趋势，且这些受体消失。在乳腺癌和子宫内膜癌中，随着分化程度降低，ER和PR的存在及浓度也会下降。受体分析在晚期乳腺癌患者内分泌治疗的患者选择中已确立地位，并且有望在子宫内膜癌和卵巢子宫内膜样癌中得到类似应用。尚不清楚无病生存期是否与肿瘤组织中ER或PR的存在或浓度本身相关。受体阳性肿瘤的乳腺癌患者生存率更高，这可能归因于对内分泌治疗的反应。子宫内膜癌患者似乎也是如此。女性性激素受体分析在乳腺癌、子宫内膜癌和卵巢癌应用方面的未来进展需要更多对照临床试验以及更先进的受体检测方法。
